Skip to content

Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products, with an emphasis on life science-based innovation and product excellence.

OUR STORY

The fundamental principle guiding our business is to bring joy and relief to everyday people and those living with medical conditions.

Emerald was founded in 2014 by a team of life scientists and doctors interested in the therapeutic effects of cannabis for people living with medical conditions. After four years of growing medical-grade cannabis for patients, we were excited to apply our experience towards producing first-rate cannabis for the legalized adult-use market in Canada. Our meticulous pharmaceutical standards are used at every step of product development, from growing and processing to R&D.

Our team of research scientists are ceaselessly working to develop new product lines containing our cannabis extracts, which offer faster onset/offset times and improved consistency and reproducibility, allowing users to better control their experience while enjoying all of the benefits that they are used to with Emerald products. Further, Emerald is committed to using the best ingredients available to support your health and well-being while enjoying cannabis responsibly.

FOCUSED ON SUSTAINABILITY

Our new craft facility was sustainability designed to reduce waste and use natural growing methods.

Emerald’s state-of-the-art facility in Metro-Vancouver, British Columbia, consists of 156,000 square feet in two-hybrid greenhouses. The facilities were built with technological advancements and operational efficiencies to reduce environmental impact and incorporate sustainable principles such as recycling water, sun-assisted lighting, and living soils. The advanced climate control system automatically takes advantage of natural sunlight, reducing high-intensity discharge lighting and energy use. Plastic consumption and carbon footprint from the transportation of materials is significantly reduced by recycling organic soils.

ORGANIC LIVING SOIL

We are focused on optimizing terpene profiles in our cannabis crops to produce excellent smelling and flavourful products.

The distinct aromas and flavours associated with various cultivars are a result of their terpene profiles. Terpenes are aromatic compounds found in cannabis and select plants and are known to have a range of therapeutic effects. For instance, linalool, found in lavender and cannabis, has a calming effect.

The best way to boost terpene profiles in cannabis is to grow the plants in natural, high-quality soil. Our living soil is made in-house and organic certified by Pro-Cert, a leading provider of professional third-party organic certification in North America. The hard work has paid off. Our plants are vibrant and healthy and bursting with delicious terpenes.

MEET OUT LEADERSHIP

At Emerald, we care about diversity and inclusion in our workplace and believe that perspectives from various backgrounds make our business model and work-culture strong. We promote and support our team by recognizing talent and performance and providing equal opportunity.

Riaz Headshot

Riaz Bandali

President and Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and, Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.

201020 Jenn Hepburn Headshot

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn brings over a decade of experience in accounting and finance to the team at Emerald Health Therapeutics. She is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Ms. Hepburn brings in-depth knowledge from her experience in ERP implementations, financings and reorganizations, as well as corporate governance, securities disclosure and stock exchange listings. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held Controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

Rebecca Wong headshot

Rebecca Wong

Vice President, Quality & Regulatory Affairs
Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies, including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

GET YOUT MIND & BODY IN SYNC

Quality cannabis oils and fast-action sprays, perfect for people interested in smoke-free relaxing products. 

Rebecca Wong

Vice President, Quality and Regulatory Affairs

Ms. Wong has more than 25 years of managerial experience in quality assurance and quality control spanning research, preclinical, clinical, and commercial phases for pharmaceuticals, combination products, biologicals and medical devices. Before joining Emerald, she was the Executive Director of Quality Assurance at Novelion Therapeutics (formerly QLT Inc.), where she was the head of quality assurance, validation, compliance auditing, document management, and GxP training departments. Ms. Wong previously worked for life science companies including MDS Nordion, Cangene Corporation, and Biomira Inc. Specializing in microbiology, she earned a BSc from the University of Alberta.

Jenn Hepburn

Chief Financial Officer

Ms. Hepburn has over a decade of experience in accounting and finance and is an experienced manager of privately and publicly traded manufacturing and mining businesses operating in Canada and the USA. Prior to joining Emerald, Ms. Hepburn was the Director of Finance and Administration at bioLytical Laboratories Inc., a medical diagnostics manufacturer. Before that, she held controller positions at junior gold and silver mining companies Northern Vertex Mining Corp., Kootenay Silver Inc. and Theia Resources Ltd. Ms. Hepburn earned a BBA from Simon Fraser University and her certification from the Certified Management Accountants of British Columbia.

RIAZ BANDALI

President & Chief Executive Officer

Mr. Bandali’s expertise in global operations, strategy development, driving innovation, M&A, and investment management has been developed over a 25-year career in the life sciences sector spanning contract clinical and research services, analytical instrumentation, lab services and venture capital.

He holds an Advanced Management Program Degree from Harvard Business School, a Master of Business Administration from McGill University, and a Bachelor of Science from the University of British Columbia. He is an innovative business leader who has built strategic and operating plans that have resulted in rapid growth and significant profitability enhancement. He has managed businesses and operations with a global footprint and has led teams of over 900 people.

Mr. Bandali’s previous experience includes serving as President, Early Phase Clinical Services and Translational Science, Syneos Health; President, Early Stage Development, as well as Chief Innovation Officer, inVentiv Health Clinical; Senior Vice President, Strategy and Business Development, AB Sciex and Molecular Devices (part of Danaher Corporation); Senior Vice President, Strategy, Legal and Corporate Development, MDS Analytical Technologies; and Vice President and General Manager, Global Early Stage Development, MDS Pharma Services. He was also Venture Partner and Vice President at MDS Capital and has served on the boards of private and public companies.